# Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

> **NCT05198505** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 280 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** TQB2868 Injection

## Key facts

- **NCT ID:** NCT05198505
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-27
- **Primary completion:** 2023-06
- **Final completion:** 2024-06
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2022-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198505, "Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05198505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*